TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02776657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Coronary Angiography
Description: This will be performed as part of usual care and does not constitute part of the research project.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Coronary Angiography
Description: This will be performed as part of usual care and does not constitute part of the research project.
Study: NCT02128763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Description: 2000 mg EPA and 1000 mg DHA per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
Study: NCT00648193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride 40 mg tablet
Description: 40mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil® 40 mg Table
Description: 40mg, single dose fasting
Study: NCT01376713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab plus Dacarbazine
Description: Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks.
Study: NCT02648958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The control group received the normal saline infusion
Study: NCT00133237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: cypher stent is implanted due to randomization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: taxus stent is implanted due to randomization.
Study: NCT02939924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kanshas DCB
Description: The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
Study: NCT02928549

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews
Study: NCT02273752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study: NCT02213497

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG (Fluorodeoxyglucose) PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT04643236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene motivation session
Description: Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
Study: NCT04485156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin
Description: 30mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 300mg
Study: NCT02213497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT00903032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care following ACS hospital discharge.
Study: NCT03443843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Description: Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Description: Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Description: Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Description: Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
Study: NCT01594671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule
Study: NCT03443843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet orally
Study: NCT04485156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: 20-30mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 20-30mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: 15-20mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 10mg/kg
Study: NCT00952718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
Study: NCT03443843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet orally
Study: NCT01114945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath
Description: Intubation with the McGrath device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: Intubation with the GlideScope device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Macintosh Laryngoscopy
Description: Intubation with Direct Macintosh Laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-Mac
Description: Intubation with the Video-Mac device
Study: NCT03769233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
Study: NCT04664049

Intervention type: DIETARY_SUPPLEMENT
Intervention: NRICM101
Description: Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm
Study: NCT01113333

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:injection~Route of administration: intra-articular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT03653013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard of care
Description: Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
Study: NCT03222570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depressed Adolescents
Description: IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depressed Adolescents
Description: IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor
Description: Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
Study: NCT03014804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells pulsed with tumor lysate antigen Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells pulsed with tumor lysate antigen Vaccine
Description: Given ID
Study: NCT03653013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Consultation
Description: Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
Study: NCT02873754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Counseling
Description: Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
Study: NCT03014804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01594671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: haemostasia
Description: The surgical habitual haemostasia: electrocoagulation of the bleeding tissues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: haemostasia
Description: The surgical habitual haemostasia: electrocoagulation of the bleeding tissues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: haemostasia
Description: The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
Study: NCT00769392

Intervention type: DRUG
Group type: OTHER
Intervention: Proparacaine Ophthalmic
Description: Drops of Proparacaine on the eye, administered as described in the package insert

Intervention type: DRUG
Group type: OTHER
Intervention: Tetracaine Ophthalmic
Description: Drops of Tetracaine on the eye, administered as described in the package insert

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 4%
Description: A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 2% Injectable Solution
Description: A subconjunctival injection of Lidocaine 2%
Study: NCT01460017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Sclerectomy
Description: Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Trab
Description: Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
Study: NCT03443843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
Study: NCT02873754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
Study: NCT03920683

Intervention type: OTHER
Intervention: Data collection
Description: Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
Study: NCT03691298

Intervention type: DEVICE
Intervention: SUTUREFIX ULTRA Suture Anchor and SUTUREFIX CURVED Suture Anchor
Description: Fixation device intended to provide secure fixation of soft tissue to bone
Study: NCT03787693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR - Virtual Reality
Description: Subjects in the experimental group will perform the split-belt task in a VR environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR - Virtual Reality
Description: Subjects in the experimental group will perform the split-belt task in a VR environment
Study: NCT01559935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
Study: NCT04370431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01 single ascending doses
Description: TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
Study: NCT02873754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
Study: NCT03547752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observed action and motor imaginery
Description: Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observed action and motor imaginery
Description: Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
Study: NCT00506181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotic mixture
Description: Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01510041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory exercise
Description: Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
Study: NCT00761930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan and fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Ingredient and fluoride
Description: Brush twice daily
Study: NCT03491696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone
Description: Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
Study: NCT04370431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for Part A of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01, 60 mg
Description: TTYP01 oral tablets (30 mg edaravone per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01, 60 mg
Description: TTYP01 oral tablets (30 mg edaravone per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01, 120 mg
Description: TTYP01 oral tablets (30 mg edaravone per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01, 120 mg
Description: TTYP01 oral tablets (30 mg edaravone per tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radicut® (ampoule), 30 mg
Description: An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radicut® (ampoule), 30 mg
Description: An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes